EXCLI J EXCLI Journal 1611-2156 Leibniz Research Centre for Working Environment and Human Factors 2017-1000 10.17179/excli2017-1000 Doc1288 Editorial material Discovering urinary bladder cancer risk variants: Status quo after almost ten years of genome-wide association studies Selinski Silvia * 1 Leibniz Research Centre for Working Environment and Human Factors (IfADo) *To whom correspondence should be addressed: Silvia Selinski, Leibniz Research Centre for Working Environment and Human Factors (IfADo), Ardeystrasse 67, 44139 Dortmund, Germany, E-mail: selinski@ifado.de 08 12 2017 2017 16 1288 1296 28 11 2017 05 12 2017 Copyright © 2017 Selinski 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.

 This article is available from http://www.excli.de/vol16/Selinski_08122017_proof.pdf 

About ten years ago Kiemeney and colleagues (2008[24]) published the first genome-wide association study (GWAS) discovering two novel single nucleotide polymorphisms (SNPs) near MYC (rs9642880) and TP63 (rs710521) associated with urinary bladder cancer (UBC) risk. Meanwhile, further GWAS and candidate gene studies identified and confirmed a number of susceptibility variants for UBC (Selinski, 2012[37], 2013[38], 2014[39]; Dudek et al., 2013[4]; Selinski et al., 2013[41]; Golka et al., 2011[18]). Currently, fifteen genomic regions seem to play a major role in development of this disease (Table 1(Tab. 1); References in Table 1: Figueroa et al., 2014[8]; Figueroa et al., 2016[7]; Fu et al., 2012[9]; Garcia-Closas et al., 2011[12]; Garcia-Closas et al., 2013[11]; Golka et al., 2009[13]; Grotenhuis et al., 2014[20]; Kiemeney et al., 2008[24]; Kiemeney et al., 2010[23]; Lehmann et al., 2010[26]; Nørskov et al., 2011[29]; Rafnar et al., 2009[31]; Rafnar et al., 2011[33]; Rafnar et al., 2014[32]; Rothman et al., 2010[34]; Selinski et al., 2011[42]; Selinski et al., 2012[44]; Tang et al., 2012[45]; Wang et al., 2014[46]; Wu et al., 2009[47]). It can be assumed that almost all relevant polymorphisms have been discovered now. The most recent UBC GWAS of Figueroa et al. (2016[7]) required 15,058 cases and 286,270 controls to discover a further susceptibility region at 13q34 (MCF2L gene), including the Icelandic and the Dutch GWAS (Gudbjartsson et al., 2015[21]; Kiemeney et al., 2008[24]). The odds ratios of the most recent UBC risk SNPs are rather small, e.g. the MCF2L intron variant rs4907479, with the strongest signal in the 2016 fine-mapping study of Figueroa et al. (2016[7]) resulted in an odds ratio (OR) of 1.13.

Several UBC risk variants are particularly relevant in persons exposed to bladder carcinogens - mainly by tobacco smoke (Burger et al., 2013[1]; Garcia-Closas et al., 2005[10], 2011[12], 2013[11]; Selinski et al., 2013[41]; Moore et al., 2011[28]) but also by occupation and environment (Ebbinghaus et al., 2017[5]; Höhne et al., 2017[22]; Krech et al., 2017[25]; Lukas et al., 2017[27]; Carreón et al., 2014[2]; Golka et al., 2012[14], 2009[13], 2004[19], 2002[15], 1997[17], 1996[16]; Delclos and Lerner, 2008[3]; Ovsiannikov et al., 2012[30]; Rushton et al., 2012[35]). However, currently no particular variant that is only relevant in exposed persons could be identified and replicated in GWAS. In 2014, Figueroa et al. (2014[6]) identified two variants in a genome-wide smoking ⨯ SNP interaction study -rs1711973 (FOXF2) relevant for never smokers and rs12216499 (RSPH2-TAGAP-EZR) in ever smokers, but both could not be confirmed using a large replication series (Figueroa et al., 2016[7]). Nevertheless, interaction analyses and stratification regarding smoking habits and cancer invasiveness are promising future approaches to uncover further susceptibility variants that are relevant for particular subgroups of the UBC patients.

A further challenge is a genome-wide search for variants associated with bladder cancer recurrence and progression. This requires a large number of UBC patients with follow-up of several years after first diagnosis. However, it can be assumed that variants relevant for UBC development are also associated with UBC recurrence. Recurrence of this tumor occurs in approximately half of the patients with a median recurrence-free time of almost one year. Selinski et al. (2017[43]) showed that the ultra-slow N-acetyltransferase 2 (NAT2) genotype was associated with a significant reduction of recurrence-free time (8.4 months) compared to rapid acetylators (11 months) and an increased recurrence risk (66 % vs. 50 %, OR=1.89, 95 % CI = 1.06-3.38). Effects were more pronounced in ultra-slow smokers (7.9 months, 73 %) indicating the relevance of gene-environment interaction also for prognosis. Correspondingly, Lukas et al. (2017[27]) showed in a series of 143 UBC cases with suspected occupational bladder cancer the importance of co-occurring susceptibility variants, particularly co-occurring GSTM1 negative and rs11892031[A/A] for UBC recurrence. They discovered that UBC cases with an elevated number of risk alleles had a significantly shorter median relapse-free time of 8 months compared to cases with few risk alleles.

According to the different importance of several genetic variants depending on exposure to bladder carcinogens, e.g. GSTM1 and NAT2, different variant combinations seem to play a major role in smokers and never smokers (Selinski et al., 2017[40]; Schwender et al., 2012[36]. Recently, Selinski et al. (2017[40]) identified and replicated in a large multi-centric case-controls series (discovery series: 2969 cases / 3285 controls, replication series: 2080 cases / 2167 controls) four-variant combinations out of twelve well-known UBC risk variants. The highest odds ratios were found in never smokers with the best combination (rs1014971[AA] ⨯ rs1058396[AG,GG] ⨯ rs11892031[AA] ⨯ rs8102137[CC,CT]) resulting in an OR of 2.59 (95 % CI = 1.93-3.47; P = 1.87 ⨯ 10-10, frequency in never smoking cases: 25 %). Odds ratios of the best combinations found in smokers were clearly lower (current smokers: 1.56, former: 2.13, ever: 1.55) and different variant combinations were relevant, especially GSTM1, rs1058396 (SLC14A1) and rs11892031 (UGT1A) combinations in current and rs9642880 (MYC), rs1495741 (NAT2) and rs8102137 (CCNE1) combinations in former smokers (Selinski et al., 2017[40]).

Burger M Catto JWF Dalbagni G Grossman HB Herr H Karakiewicz P Epidemiology and risk factors of urothelial bladder cancer Eur Urol 2013 63 234 241 Carreón T Hein MJ Hanley KW Viet SM Ruder AM Bladder cancer incidence among workers exposed to o-toluidine, aniline and nitrobenzene at a rubber chemical manufacturing plant Occup Environ Med 2014 71 175 182 Delclos GL Lerner SP Occupational risk factors Scand J Urol Nephrol 2008 42 58 63 Dudek AM Grotenhuis AJ Vermeulen SH Kiemeney LA Verhaegh GW Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms? Int J Mol Sci 2013 14 12346 12366 Ebbinghaus D Bánfi G Selinski S Blaszkewicz M Bürger H Hengstler JG Polymorphisms of xenobiotic metabolizing enzymes in bladder cancer patients of the Semmelweis University Budapest, Hungary J Toxicol Environ Health A 2017 80 423 429 Figueroa JD Han SS Garcia-Closas M Baris D Jacobs EJ Kogevinas M Genome-wide interaction study of smoking and bladder cancer risk Carcinogenesis 2014 35 1737 1744 Figueroa JD Middlebrooks CD Banday AR Ye Y Garcia-Closas M Chatterjee N Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry Hum Mol Genet 2016 25 1203 1214 Figueroa JD Ye Y Siddiq A Garcia-Closas M Chatterjee N Prokunina-Olsson L Genome-wide association study identifies multiple loci associated with bladder cancer risk Hum Mol Genet 2014 23 1387 1398 Fu YP Kohaar I Rothman N Earl J Figueroa JD Ye Y Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk Proc Natl Acad Sci U S A 2012 109 4974 4979 Garcia-Closas M Malats N Silverman D Dosemeci M Kogevinas M Hein DW NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses Lancet 2005 366 649 659 Garcia-Closas M Rothman N Figueroa JD Prokunina-Olsson L Han SS Baris D Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer Cancer Res 2013 73 2211 2220 Garcia-Closas M Ye Y Rothman N Figueroa JD Malats N Dinney CP A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3 Hum Mol Genet 2011 20 4282 4289 Golka K Hermes M Selinski S Blaszkewicz M Bolt HM Roth G Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure Pharmacogenet Genom 2009 19 903 906 Golka K Kopps S Prager HM von Mende S Thiel R Jungmann O Bladder cancer in crack testers applying azo dye-based sprays to metal bodies J Toxicol Environ Health A 2012 75 566 571 Golka K Prior V Blaszkewicz M Bolt HM The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences Toxicol Lett 2002 128 229 241 Golka K Prior V Blaszkewicz M Cascorbi I Schöps W Kierfeld G Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany Scand J Work Environ Health 1996 22 332 338 Golka K Reckwitz T Kempkes M Cascorbi I Blaskewicz M Reich SE N-Acetyltransferase 2 (NAT2) and glutathione S-transferase µ (GSTM1) in bladder-cancer patients in a highly industrialized area Int J Occup Environ Health 1997 3 105 110 Golka K Selinski S Lehmann ML Blaszkewicz M Marchan R Ickstadt K Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs" Arch Toxicol 2011 85 539 554 Golka K Wiese A Assennato G Bolt HM Occupational exposure and urological cancer World J Urol 2004 21 382 391 Grotenhuis AJ Dudek AM Verhaegh GW Witjes JA Aben KK van der Marel SL Prognostic relevance of urinary bladder cancer susceptibility Loci PLoS ONE 2014 9 e89164 Gudbjartsson DF Helgason H Gudjonsson SA Zink F Oddson A Gylfason A Large-scale whole-genome sequencing of the Icelandic population Nat Genet 2015 47 435 444 Höhne S Gerullis H Blaszkewicz M Selinski S Hengstler JG Otto T N-acetyltransferase 1*10 genotype in bladder cancer patients J Toxicol Environ Health A 2017 80 417 422 Kiemeney LA Sulem P Besenbacher S Vermeulen SH Sigurdsson A Thorleifsson G A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer Nat Genet 2010 42 415 419 Kiemeney LA Thorlacius S Sulem P Geller F Aben KK Stacey SN Sequence variant on 8q24 confers susceptibility to urinary bladder cancer Nat Genet 2008 40 1307 1312 Krech E Selinski S Blaszkewicz M Bürger H Kadhum T Hengstler JG Urinary bladder cancer risk factors in an area of former coal, iron, and steel industries in Germany J Toxicol Environ Health A 2017 80 430 438 Lehmann ML Selinski S Blaszkewicz M Orlich M Ovsiannikov D Moormann O Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk Arch Toxicol 2010 84 967 978 Lukas C Selinski S Prager HM Blaszkewicz M Hengstler JG Golka K Occupational bladder cancer: Polymorphisms of xenobiotic metabolizing enzymes, exposures, and prognosis J Toxicol Environ Health A 2017 80 439 452 Moore LE Baris DR Figueroa JD Garcia-Closas M Karagas MR Schwenn MR GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis Carcinogenesis 2011 32 182 189 Nørskov MS Frikke-Schmidt R Bojesen SE Nordestgaard BG Loft S Tybjærg-Hansen A Copy number variation in glutathione-S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population Pharmacogenomics J 2011 11 292 299 Ovsiannikov D Selinski S Lehmann ML Blaszkewicz M Moormann O Haenel MW Polymorphic enzymes, urinary bladder cancer risk, and structural change in the local industry J Toxicol Environ Health A 2012 75 557 565 Rafnar T Sulem P Stacey SN Geller F Gudmundsson J Sigurdsson A Sequence variants at the TERT-CLPTM1L locus associate with many cancer types Nat Genet 2009 41 221 227 Rafnar T Sulem P Thorleifsson G Vermeulen SH Helgason H Saemundsdottir J Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer Hum Mol Genet 2014 23 5545 5557 Rafnar T Vermeulen SH Sulem P Thorleifsson G Aben KK Witjes JA European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene Hum Mol Genet 2011 20 4268 4281 Rothman N Garcia-Closas M Chatterjee N Malats N Wu X Figueroa JD A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci Nat Genet 2010 42 978 984 Rushton L Hutchings SJ Fortunato L Young C Evans GS Brown T Occupational cancer burden in Great Britain Br J Cancer 2012 107 S3 S7 Schwender H Selinski S Blaszkewicz M Marchan R Ickstadt K Golka K Distinct SNP combinations confer susceptibility to urinary bladder cancer in smokers and non-smokers PLoS ONE 2012 7 e51880. Erratum in PLoS ONE. 2015 Selinski S Genetic variants confer susceptibility to urinary bladder cancer: an updated list of confirmed polymorphisms EXCLI J 2012 11 743 747 Selinski S Highlight report: functional consequences of urinary bladder cancer risk variants EXCLI J 2013 12 1017 1019 Selinski S Urinary bladder cancer risk variants: recent findings and new challenges of GWAS and confirmatory studies Arch Toxicol 2014 88 1469 1475 Selinski S Blaszkewicz M Ickstadt K Gerullis H Otto T Roth E Identification and replication of the interplay of four genetic high risk variants for urinary bladder cancer Carcinogenesis 2017 epub ahead of print Available from: http://dx.doi.org/10.1093/carcin/bgx102 Selinski S Blaszkewicz M Ickstadt K Hengstler JG Golka K Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk Arch Toxicol 2013 87 2129 2139 Selinski S Blaszkewicz M Lehmann ML Ovsiannikov D Moormann O Guballa C Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype Pharmacogenet Genomics 2011 21 673 678 Selinski S Gerullis H Otto T Roth E Volkert F Ovsiannikov D Ultra-slow N-acetyltransferase 2 is associated with recurrence-free time in bladder cancer patients Eur Urol 2017 71 994 995 Selinski S Lehmann ML Blaszkewicz M Ovsiannikov D Moormann O Guballa C Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk Arch Toxicol 2012 86 1369 1378 Tang W Fu YP Figueroa JD Malats N Garcia-Closas M Chatterjee N Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer Hum Mol Genet 2012 21 1918 1930 Wang M Chu H Lv Q Wang L Yuan L Fu G Cumulative effect of genome-wide association study-identified genetic variants for bladder cancer Int J Cancer 2014 135 2653 2660 Wu X Ye Y Kiemeney LA Sulem P Rafnar T Matullo G Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer Nat Genet 2009 41 991 5. Erratum in Nat Genet. 2009 Currently confirmed polymorphisms that are associated with UBC risk, their association with bladder carcinogen exposure and prognosis (update of Selinski, 2014) according to Selinski (2014). Polymorphisms, associated genes and locations are printed in bold, risk alleles or genotypes are given in brackets.